Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | PORTIA: tisagenlecleucel and pembrolizumab in R/R DLBCL

Edmund Waller, MD, PhD, FACP, of the Division of Hematology/Oncology, Emory Clinic, Atlanta, GA, discusses the safety and efficacy results of the PORTIA study (NCT03630159), a Phase Ib trial of tisagenlecleucel and pembrolizumab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).